영어에서 FACTOR VIII 의 뜻은 무엇인가요?
요인 VIII
Factor VIII는 항 혈우병 인자로도 알려져있는 필수 혈액 응고 단백질입니다. 인간에서 인자 VIII는 F8 유전자에 의해 암호화됩니다. 이 유전자의 결핍은 열성 X 연결 응고 장애인 혈우병 A를 초래합니다. Factor VIII는간에있는 간 정현파 세포와 내피 세포에서 생성됩니다. 이 단백질은 von Willebrand factor라고 불리는 다른 분자에 결합 된 비활성 형태의 혈류를 순환하여 혈관에 손상을 입히는 손상이 발생할 때까지 계속됩니다. 상해에 응하여 응고 인자 VIII가 활성화되어 폰 빌레 브란트 인자와 분리됩니다. 활성 단백질은 인자 IX 라 불리는 다른 응고 인자와 상호 작용합니다. 이 상호 작용은 혈액 응고를 형성하는 추가 화학 반응 체인을 시작합니다. Factor VIII는 혈액 응고에 관여합니다. 그것은 Ca2 + 및 인지질의 존재 하에서 인자 X를 활성화 된 형태 Xa로 전환시키는 복합체를 형성하는 인자 IXa에 대한 보조 인자이다. 인자 VIII 유전자는 두 개의 택일 적으로 접합 된 전사 물을 생성한다.
영어 사전에서 factor VIII 의 정의
사전에있는 인자 VIII의 정의는 혈액 응고에 관여하는 단백질입니다. 기증 된 혈청에서 추출되어 가장 흔한 유형의 혈우병 치료에 사용되며, 결핵은 존재하지 않습니다.
«FACTOR VIII» 관련 영어 책
다음 도서 목록 항목에서
factor VIII 의 용법을 확인하세요.
factor VIII 에 관련된 책과 해당 책의 짧은 발췌문을 통해 영어 서적에서 단어가 사용되는 맥락을 제공합니다.
1
Factor VIII - von WIllebrand
Factor
In volume I (Subtitled: Biochemical, methodological and functional aspects), the purification and structure/function relationships of VIII and vWf are extensively reviewed with the relevance of advances in these areas to improved ...
M. J. Seghatchian, G. F. Savidge,
1989
2
Disorders of Thrombosis and Hemostasis: Clinical and ...
One BU is defined as the amount of anti-factor VIII necessary to neutralize 50% of
factor VIII in 1 mL of pooled normal plasma after incubation for 2 hours at 37°C.
The Bethesda assay can be adapted for the determination of the titer of inhibitor ...
3
Clinical Laboratory Medicine
LABORATORY RESULTS IN HEMOPHILIA A PT APTT Bleeding Time Platelet
Count Factor VIII:C Assay Normal Abnormal* Normal Normal Abnormal APTT,
activated partial thromboplastin time. PT, prothrombin time The APTT may be ...
Kenneth D. McClatchey,
2002
4
Hematology: Clinical Principles and Applications
Because factor VIII has a half-life of 8 to 12 hours, infusions are required at least
twice per day. Many hemophiliacs maintain themselves on a steady prophylactic
dose designed to keep the factor VIII level greater than 1%.63 Although initially ...
5
Wintrobe's Clinical Hematology
Factor VIII, or antihemophilic factor, is a nonenzymatic procofac- tor that circulates
in plasma in complex with the large multimeric protein vWF. Initially, factor VIII
and vWF were thought to be a single entity, and early reports on factor VIII were ...
6
Blood Banking and Transfusion Medicine: Basic Principles & ...
In the United States, current use of cryoprecipitate is almost exclusively limited to
the replacement of fibrinogen in hypofibrinogenemic patients. However, prior to
the advent of purified factor VIII, cryoprecipitate was the mainstay of treatment for
...
Christopher D. Hillyer,
2007
7
Recombinant Protein Drugs
FVIII Figure 4. Derivation of factor VIII and von Willebrand factor coexpressing
CHO cells used for the manufacture of recombinant factor IX. Adapted from
Kaufman [45] with permission. Plasmids encoding DHFR and factor VIII were
transfected ...
8
Textbook of Pediatric Emergency Medicine
When plasma is frozen and then slowly thawed, the precipitate that forms
contains enriched factor VIII coagulant activity, VWF, fibrinogen, and factor XIII.
However, like fresh-frozen plasma, the actual amount of these clotting factors in a
single ...
Gary R. Fleisher, Stephen Ludwig,
2010
9
Hemostasis and Thrombosis: Basic Principles and Clinical ...
Factor VIII circulates in plasma in an inactive form that is proteolytically cleaved
by factor Xa and/or thrombin to yield activated factor VIIIa. Factor VIIIa serves as a
cofactor for factor IXa-mediated proteolytic activation of factor X. Subsequently, ...
10
Critical Care Obstetrics
The second treatment option consists of factor VIII and vWF replacement. Fresh
frozen plasma contains both factors, but large volumes are required to stop or
prevent bleeding. Cryoprecipitate contains 5–10 times higher concentration of
both ...
George R. Saade, Michael R. Foley, Jeffrey P. Phelan,
2010
«FACTOR VIII» 단어를 포함하는 뉴스 기사
다음 뉴스 기사의 맥락에서 국내 및 국제 언론이 말하는 내용 및
factor VIII 단어를 사용하는 방법을 알아보세요.
Xenetic Biosciences Completes $3000000 Bridge Note Financing
... series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology ... «GlobeNewswire, 7월 15»
Moves to protect availability of haemophilia treatments
In changes to take effect from 1 September, PHARMAC is moving to have a preferred brand of recombinant Factor VIII, while also maintaining ... «PharmiWeb.com, 7월 15»
Competition Rising for Baxalta
Baxalta should gain approval for twice-weekly Factor VIII protein BAX 855 in late 2015, but more convenient (perhaps once-monthly) treatments ... «Morningstar.com, 7월 15»
Baxalta: A Spin-Off That Could Be Revalued Up To 50% Higher
... generic version of Baxalta's Advate, many companies will simply not be able to replicate a large, relatively unstable protein that is Factor VIII. «Seeking Alpha, 7월 15»
EXCLUSIVE: I saw all three of my brothers die after they were given …
He became infected with HIV, Hepatitis C, Hepatitis B, Cytomegalovirus (CMV) and the human herpes virus after receiving Factor VIII blood ... «Express.co.uk, 7월 15»
ALJ Lord sets 16-month target date in Certain Recombinant Factor …
On May 26, 2015, ALJ Dee Lord issued Order No. 3 in Certain Recombinant Factor VIII Products (Inv. No. 337-TA-956). By way of background, ... «Lexology, 7월 15»
Bayer Files Hemophilia A Drug Marketing Application in Japan
BAY 94-9027 is a site-specific PEGylated recombinant factor VIII. BAY 94-9027, currently in phase III, is being developed for patients suffering ... «Zacks.com, 7월 15»
Baxalta Spins Off from Baxter
... Complex (Human)] with new offerings that include BAX 855, an extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A to ... «Genetic Engineering & Biotechnology News, 7월 15»
Bayer Yakuhin seeks Japanese marketing nod for recombinant …
BAY 81-8973 is a full-length recombinant factor VIII which has shown clinical benefit of efficacy when used for prophylaxis twice or three times ... «pharmabiz.com, 6월 15»
BRIEF-Bayer submits application for recombinant factor compound …
Bayer submits an application for market authorization of recombinant factor VIII product as a treatment of hemophilia a in Japan Further ... «Reuters, 6월 15»